A Randomized Controlled Trial of Mindfulness-Based Cognitive Therapy for Treatment-Resistant Depression.
Study Goal
The researchers aimed to evaluate the efficacy of mindfulness-based cognitive therapy (MBCT) compared to an active control (HEP) as adjuncts to pharmacotherapy in adults with treatment-resistant depression (TRD).
Results Summary
MBCT showed a significantly greater reduction in depression severity (36.6% vs. 25.3%) and higher treatment response rates (30.3% vs. 15.3%) compared to HEP, though remission rates did not differ significantly. State anxiety, perceived stress, and personality disorders negatively impacted outcomes.
Population
Outpatient adults with treatment-resistant depression (mean current depressive episode duration: 6.8 years).
Effective Dosage
8-week course (specific session frequency not detailed).
Duration
8 weeks.
Interactions
None mentioned.
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
mindfulness-based cognitive therapy (MBCT) | decrease | HAM-D17 total score | outpatient adults with treatment-resistant depression (TRD) | 36.6% vs. 25.3% | was associated with a significantly greater mean percent reduction | #1 |
mindfulness-based cognitive therapy (MBCT) | increase | treatment responders | outpatient adults with treatment-resistant depression (TRD) | 30.3% vs. 15.3% | was associated with a significantly higher rate | #2 |
mindfulness-based cognitive therapy (MBCT) | no change | rates of remission | outpatient adults with treatment-resistant depression (TRD) | 22.4% vs. 13.9% | did not significantly differ | #3 |
state anxiety | neutral | outcomes | outpatient adults with treatment-resistant depression (TRD) | - | had adverse effects | #4 |
perceived stress | neutral | outcomes | outpatient adults with treatment-resistant depression (TRD) | - | had adverse effects | #5 |
presence of personality disorder | neutral | outcomes | outpatient adults with treatment-resistant depression (TRD) | - | had adverse effects | #6 |
mindfulness-based cognitive therapy (MBCT) | decrease | depression severity | outpatient adults with treatment-resistant depression (TRD) | - | significantly decreased | #7 |
mindfulness-based cognitive therapy (MBCT) | increase | treatment response rates | outpatient adults with treatment-resistant depression (TRD) | - | improved | #8 |
mindfulness-based cognitive therapy (MBCT) | no change | remission rates | outpatient adults with treatment-resistant depression (TRD) | - | not | #9 |
BACKGROUND: Due to the clinical challenges of treatment-resistant depression (TRD), we evaluated the efficacy of mindfulness-based cognitive therapy (MBCT) relative to a structurally equivalent active comparison condition as adjuncts to treatment-as-usual (TAU) pharmacotherapy in TRD. METHODS: This single-site, randomized controlled trial compared 8-week courses of MBCT and the Health Enhancement Program (HEP), comprising physical fitness, music therapy and nutritional education, as adjuncts to TAU pharmacotherapy for outpatient adults with TRD. The primary outcome was change in depression severity, measured by percent reduction in the total score on the 17-item Hamilton Depression Rating Scale (HAM-D17), with secondary depression indicators of treatment response and remission. RESULTS: We enrolled 173 adults; mean length of a current depressive episode was 6.8 years (SD = 8.9). At the end of 8 weeks of treatment, a multivariate analysis showed that relative to the HEP condition, the MBCT condition was associated with a significantly greater mean percent reduction in the HAM-D17 (36.6 vs. 25.3%; p = 0.01) and a significantly higher rate of treatment responders (30.3 vs. 15.3%; p = 0.03). Although numerically superior for MBCT than for HEP, the rates of remission did not significantly differ between treatments (22.4 vs. 13.9%; p = 0.15). In these models, state anxiety, perceived stress and the presence of personality disorder had adverse effects on outcomes. CONCLUSIONS: MBCT significantly decreased depression severity and improved treatment response rates at 8 weeks but not remission rates. MBCT appears to be a viable adjunct in the management of TRD.